Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Has announcements × mCRPC × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 39 Breast Neoplasms 28 Parkinson Disease 4, Autosomal Dominant Lewy Body 21 Neoplasms 20 Multiple Myeloma 18 Leukemia, Myeloid, Acute 13 Melanoma 11 Neoplasm Metastasis 11 Carcinoma, Renal Cell 10 Leukemia 10 Precursor Cell Lymphoblastic Leukemia-Lymphoma 10 Recurrence 10 Leukemia, Lymphocytic, Chronic, B-Cell 9 Ovarian Neoplasms 9 Adenocarcinoma 8 Carcinoma, Hepatocellular 8 Colorectal Neoplasms 8 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8 Prostatic Neoplasms 8 Lung Neoplasms 7 Lymphoma, Follicular 7 Myelodysplastic Syndromes 7 Carcinoma 6 Lymphoma 6 Lymphoma, Non-Hodgkin 6 Small Cell Lung Carcinoma 6 Urinary Bladder Neoplasms 6 Bronchiolitis Obliterans Syndrome 5 Esophageal Neoplasms 5 Fallopian Tube Neoplasms 5

Interventions

talazoparib 1 enzalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03395197 2026-03-12

TALAPRO-2

Pfizer

Phase 3 Active not recruiting

1,054 enrolled 21 charts 1 FDA

mCRPC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡